The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms
The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms
复制标题
DOI：
10.3390/diagnostics10010038
复制
发表时间：
2020-01-01
期刊：
影响因子：
3.6
通讯作者：
Laktionov, Pavel P.
中科院分区：
文献类型：
--
作者：
Konoshenko, Maria Yu;Lekchnov, Evgeniy A.;Laktionov, Pavel P.
前列腺癌是一个全球性的生物学、医学和社会问题，缺乏可靠、高度特异和敏感的非侵入性检查来诊断和分期前列腺癌。生物标志物的一个潜在来源是存在于各种生物液中的无细胞miRNAs。在本研究中，我们验证了无细胞miRNAs：miR-19b、miR-22、miR-92a、miR-378、miR-425、miR-30e、miR-31、miR-125b、miR-200b、miR-205、miR-375和miR-660的诊断潜力；我们估计了后续大规模验证研究所需的样本量和最小miRNA集。研究了前列腺癌(n=10)、良性前列腺增生症(n=8)和健康志愿者(n=11)三种生物体液(尿液、透明尿液和血浆)中12种miRNA的相对表达。在尿囊中发现的8个miRNAs(miR-19b、miR-30e、miR-31、miR-92a、miR-125、miR-200、miR-205和miR-660)显示出很好的前景，当组合成6个比率(miR-125b/miR-30e、miR-200/miR-30e、miR-205/miR-30e、miR-31/miR-30e、miR-660/miR-30e和miR-19b/miR-92a)时，可以100%特异性、100%敏感性和100%区分前列腺癌、良性增生和健康捐赠者。而且对大多数捐赠者来说都是高度可靠的。
Prostate cancer is a global biological, medical, and social issue aggravated by the lack of reliable, highly specific, and sensitive non-invasive tests for diagnosis and staging of prostate cancer. One prospective source of biomarkers are the cell-free miRNAs present in various biological fluids. In the present study, we validated the diagnostic potential of cell-free miRNAs: miR-19b, miR-22, miR-92a, miR-378, miR-425, miR-30e, miR-31, miR-125b, miR-200b, miR-205, miR-375, and miR-660; we estimated the required sample size and the minimal miRNA set for a subsequent large-scale validation study. Relative expression of 12 miRNA combined in 31 ratios was investigated in three fractions of biological fluids (urine extracellular vesicles, clarified urine, and plasma) obtained from patients with prostate cancer (n = 10), benign prostate hyperplasia (n = 8), and healthy volunteers (n = 11). Eight of the miRNAs found in urine vesicles (miR-19b, miR-30e, miR-31, miR-92a, miR-125, miR-200, miR-205, and miR-660) showed great promise and when combined into six ratios (miR-125b/miR-30e, miR-200/miR-30e, miR-205/miR-30e, miR-31/miR-30e, miR-660/miR-30e, and miR-19b/miR-92a) could classify patients with prostate cancer, benign prostate hyperplasia, and healthy donors with 100% specificity, 100% sensitivity, and with a high degree of reliability for most donors.